Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 3351 to 3400 of 3807 results for treatment

  1. Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (TA381)

    This guidance has been updated and replaced by NICE technology appraisal guidance 908.

    Withdrawn guidance

  2. SeQuent Please Neo balloon catheter for in-stent coronary restenosis - update of MTG1 (discontinued)

    Discontinued Reference number: GID-MT516

    Medical technologies guidance
    Discontinued

  3. Multiple sclerosis - sativex [ID387]

    Discontinued Reference number: GID-TAG368

    Technology appraisal guidance
    Discontinued

  4. Suction diathermy adenoidectomy (HTG209)

    Evidence-based recommendations on suction diathermy adenoidectomy. This involves using heat and suction to remove the adenoids.

    HealthTech guidance
    Published
    16 December 2009
    View recommendations

    Sections for HTG209

  5. Evidence on the safety and efficacy of intramedullary distraction for upper limb lengthening is inadequate in quantity and quality. But because this is a rare condition with limited alternative treatments, the procedure can be considered as long as special arrangements for clinical governance, consent, and audit or research are in place. Find out what special arrangements mean on the NICE interventional procedures guidance page. Further research, which could be registry data, should report details of patient  selection, device selection, technique used, procedural outcomes, long-term  outcomes including quality of life, the need for repeat interventions or surgery and complication rates.

    quality. But because this is a rare condition with limited alternative treatments, the procedure can be considered as long as special...

    Research recommendation
    Published
    11 May 2022

  6. Mental wellbeing of older people in care homes (QS50)

    This quality standard covers the mental wellbeing of older people (aged 65 and over) receiving care in care homes (including residential and nursing accommodation, day care and respite care). It focuses on support for people to improve their mental wellbeing so that they can stay as well and independent as possible. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    12 December 2013
    View quality statements

    Sections for QS50

  7. About our guidance

    Our guidance is developed by independent committees, including professionals and lay members, and consulted on by stakeholders.

  8. Radiofrequency ablation for atrial fibrillation in association with other cardiac surgery (HTG72)

    Evidence-based recommendations on radiofrequency ablation for atrial fibrillation in association with other cardiac surgery. This involves scarring the heart tissue using heat to interrupt abnormal electrical signals.

    HealthTech guidance
    Published
    25 May 2005
    View recommendations

    Sections for HTG72

  9. Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labour (HTG744)

    Evidence-based recommendations on balloon disimpaction of the baby’s head at emergency caesarean during the second stage of labour. This involves inserting a silicone balloon into the vagina and inflating to lift the baby’s head before starting the caesarean.

    HealthTech guidance
    Published
    23 April 2025
    View recommendations

    Sections for HTG744

  10. VEST external stent for coronary artery bypass grafts (MIB115)

    NICE has developed a medtech innovation briefing (MIB) on the VEST external stent for coronary artery bypass grafts .

    Medtech innovation briefing
    Published
    2 August 2017

  11. Voxelotor for treating haemolytic anaemia caused by sickle cell disease (TA981)

    NICE has withdrawn this guidance. Pfizer has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that the product is being withdrawn. The recall notification is being shared with all healthcare professionals. No new people will start taking voxelotor in the UK. Healthcare professionals should discuss alternative treatment options with people currently having voxelotor.

    Withdrawn guidance

  12. Microwave ablation for atrial fibrillation in association with other cardiac surgery (HTG73)

    Evidence-based recommendations on microwave ablation for atrial fibrillation in association with other cardiac surgery. This involves scarring the heart tissue using heat produced from microwave energy to interrupt abnormal electrical signals.

    HealthTech guidance
    Published
    25 May 2005
    View recommendations

    Sections for HTG73

  13. Lower limb deep vein valve reconstruction for chronic deep venous incompetence (HTG141)

    Evidence-based recommendations on lower limb deep vein valve reconstruction for chronic deep venous incompetence. This involves restructuring valves in the deep veins of the legs by various surgical techniques, such as using stitches to repair the valve.

    HealthTech guidance
    Published
    23 May 2007
    View recommendations

    Sections for HTG141

  14. Blogs

    EQ-5D-5L value set and how it has the potential to help us decide if new treatments offer good value for money for the NHS. Sophie...

  15. Fees for technology appraisals and highly specialised technologies

    NICE fees for technology appraisals and highly specialised technologies

  16. Charging timeline

    A timeline showing where in the NICE evaluation process companies will be charged.

  17. Sunlight exposure: risks and benefits (NG34)

    This guideline covers how to communicate the risks and benefits of natural sunlight exposure (specifically, the ultraviolet rays UVA and UVB) to help people understand why they may need to modify their behaviour to reduce their risk of skin cancer and vitamin D deficiency.

    NICE guideline
    Published
    9 February 2016
    View recommendations

    Sections for NG34

  18. Mega Soft Patient Return Electrode for use during monopolar electrosurgery (HTG290)

    Evidence-based recommendations on Mega Soft Patient Return Electrode for use during monopolar electrosurgery.

    HealthTech guidance
    Published
    22 August 2012
    View recommendations

    Sections for HTG290

  19. U-Drain for people needing night drainage of urine or dialysis fluid (MIB95)

    NICE has developed a medtech innovation briefing (MIB) on U-Drain for people needing night drainage of urine or dialysis fluid .

    Medtech innovation briefing
    Published
    9 February 2017

  20. Technology appraisal submission templates and supporting documents

    All the templates and supporting documents you need to make a technology appraisals submission with NICE.

  21. Ultrasound-guided regional nerve block (HTG179)

    Evidence-based recommendations on ultrasound-guided regional nerve block. This involves using ultrasound guidance to position needles that deliver local anaesthetic in the correct place next to the nerves.

    HealthTech guidance
    Published
    28 January 2009
    View recommendations

    Sections for HTG179

  22. NICE Listens

    NICE Listens is our programme of deliberative public engagement. It's used to give us an understanding of public opinion on moral, ethical and social value issues.

  23. PneuX to prevent ventilator-associated pneumonia (HTG543)

    Evidence-based recommendations on PneuX to prevent ventilator-associated pneumonia.

    HealthTech guidance
    Published
    8 April 2020
    View recommendations

    Sections for HTG543

  24. Epiduroscopic lumbar discectomy via the sacral hiatus for sciatica

    Discontinued Reference number: GID-IP2806

    Interventional procedures guidance
    Discontinued

  25. Osteoarthritis - diacerein [ID332]

    Discontinued Reference number: GID-TAG250

    Technology appraisal guidance
    Discontinued

  26. Cochlear implants for children and adults with severe to profound deafness (TA566)

    Evidence-based recommendations on cochlear implants for children and adults with severe to profound deafness.

    Technology appraisal guidance
    Published
    7 March 2019
    View recommendations

    Sections for TA566

  27. Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]

    Discontinued Reference number: GID-TAG363

    Technology appraisal guidance
    Discontinued

  28. Insertion of metal rib reinforcements to stabilise a flail chest wall (HTG234)

    Evidence-based recommendations on insertion of metal rib reinforcements to stabilise a flail chest wall. This involves using metal (usually titanium) to stabilise the ‘flail’ segment of chest wall.

    HealthTech guidance
    Published
    27 October 2010
    View recommendations

    Sections for HTG234

  29. UK licensing and technology appraisals

    NICE has a key role in UK licensing and the evaluation of and access to new and innovative products for the health system.

  30. Contributing to the development of our guidance

    We've created the guides and resources on this page to help people who are involved in developing NICE guidelines.

  31. Contributing to the development of our guidance

    We've created the guides and resources on this page to help people who are involved in developing NICE guidelines.

  32. Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]

    Discontinued Reference number: GID-TAG411

    Technology appraisal guidance
    Discontinued

  33. Lapatinib for breast cancer (for use in women with previously treated advanced or metastatic breast cancer) [ID20]

    Discontinued Reference number: GID-TAG387

    Technology appraisal guidance
    Discontinued

  34. Preventing suicide in community and custodial settings (NG105)

    This guideline covers ways to reduce suicide and help people bereaved or affected by suicides. It aims to:

    NICE guideline
    Published
    10 September 2018
    View recommendations

    Sections for NG105

  35. Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]

    In development Reference number: GID-TAG406 Expected publication date: TBC

    Technology appraisal guidance
    In development

  36. Lapatinib for breast cancer (first line use in advanced or metastatic hormone-sensitive breast cancer) [ID115]

    Discontinued Reference number: GID-TAG404

    Technology appraisal guidance
    Discontinued

  37. Planning your technology appraisal submission to NICE

    Engage at the optimal time for your technology appraisal, to achieve NICE guidance at the same time as marketing authorisation.

  38. Percutaneous laser atherectomy as an adjunct to balloon angioplasty (with or without stenting) for peripheral arterial disease (HTG294)

    Evidence-based recommendations on percutaneous laser atherectomy as an adjunct to balloon angioplasty (with or without stenting) for peripheral arterial disease. This involves using a baloon to widen the artery at the site of the blockage.

    HealthTech guidance
    Published
    27 November 2012
    View recommendations

    Sections for HTG294

  39. Endoaortic balloon occlusion for cardiac surgery (HTG168)

    Evidence-based recommendations on endoaortic balloon occlusion for cardiac surgery. This involves inserting a tube with a balloon attached into the aorta and filling it with saline to block blood flowing from the heart so that surgery can be done.

    HealthTech guidance
    Published
    28 May 2008
    View recommendations

    Sections for HTG168

  40. Smoking: reducing and preventing tobacco use (QS82)

    This quality standard covers reducing and preventing tobacco use in adults, young people and children. It includes interventions to discourage people from taking up smoking, tobacco control strategies and smokefree policies. It is particularly relevant to local authorities, schools and colleges, employers and NHS service providers. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    25 March 2015
    View quality statements

    Sections for QS82

  41. Multiple sclerosis (primary-progressive) - fingolimod [ID62]

    Discontinued Reference number: GID-TAG221

    Technology appraisal guidance
    Discontinued

  42. Visensia for early detection of deteriorating vital signs in adults in hospital (MIB36)

    NICE has developed a medtech innovation briefing (MIB) on Visensia for early detection of deteriorating vital signs in adults in hospital

    Medtech innovation briefing
    Published
    5 August 2015

  43. Atrial fibrillation - ximelagatran [ID376]

    Discontinued Reference number: GID-TAG377

    Technology appraisal guidance
    Discontinued

  44. Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus (HTG165)

    Evidence-based recommendations on allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus. This involves removing cells called islet cells, which are responsible for the production of insulin, from human donors.

    HealthTech guidance
    Published
    23 April 2008
    View recommendations

    Sections for HTG165

  45. Saving babies' hearing: how a world-first rapid genetic test is transforming neonatal care

    Learn how NICE's healthtech guidance helped bring life-changing genetic testing to neonatal units across the UK, saving 20 babies' hearing so far with potential to prevent hearing loss in 200 babies annually.

    News
    Last updated
    23 March 2026

  46. Bimekizumab for treating active non-radiographic axial spondyloarthritis [ID4010]

    Discontinued Reference number: GID-TA11151

    Technology appraisal guidance
    Discontinued

  47. Colon cancer (adjuvant) - irinotecan [ID379]

    Discontinued Reference number: GID-TAG380

    Technology appraisal guidance
    Discontinued

  48. Juvenile idiopathic arthritis - adalimumab [ID385]

    Discontinued Reference number: GID-TAG400

    Technology appraisal guidance
    Discontinued

  49. Etirinotecan pegol for treating breast cancer with brain metastases [ID881]

    Discontinued Reference number: GID-TA10066

    Technology appraisal guidance
    Discontinued

  50. Renal cell carcinoma - sunitinib [ID1076]

    Discontinued Reference number: GID-TA10166

    Technology appraisal guidance
    Discontinued